Appendix 1. Bibliography

Articles Accepted for Efficacy Analysis


17. Donikyan LA. A double-blind randomized, placebo-controlled, multicenter clinical study to evaluate the safety and efficacy of a natural herbal formulation when taken as recommended for weight control. Boca Raton, FL: Rexall Sundown. 2002. [Rec#: 509]


27. Jonderko K, Kucio C. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. Aliment Pharmacol Ther. 1991;5:(4)413-8. [Rec#: 137]


51. Shugarman AE. Effect of thermogenic dietary supplements on resting metabolic rate in healthy male and female volunteers. Utah: University of Utah. 1998. [Rec#: 305]


53. Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. BMJ. 1997;314:(7073)29-34. [Rec#: 261]


Articles Rejected from Efficacy Analysis


Articles Excluded from Efficacy Analysis (continued)


34. Baselt RC. Ephedra. In: Baselt RC. (Ed) Disposition of Toxic Drugs and Chemicals in Man (2nd). Foster City, CA: Chemical Toxicology Institute. 1982a. [Rec#: 21]


Articles Excluded from Efficacy Analysis (continued)


46. Blenkinsopp A, Bradley C. Patients, society, and the increase in self medication. BMJ. 1996;312;(7031)629-32. [Rec#: 533]

47. Blumenthal M. FDA Holds Expert Advisory Committee Hearing on Ma Huang: Experts Recommend Appropriate Labeling and Warnings - Not Banning the Herb. HERBALGRAM. 1996;36:21-3, 73. [Rec#: 32]


53. Boston LN. Dysuria following ephedrine therapy. The Medical Times. 1928;56;(Apr)94-95. [Rec#: 302]

Articles Excluded from Efficacy Analysis (continued)

55. Bowyer JF, Newport GD, Slikker W Jr., Gough B, Ferguson SA, Tor-Agbidye J. An evaluation of l-ephedrine neurotoxicity with respect to hyperthermia and caudate/putamen microdialysate levels of ephedrine, dopamine, serotonin, and glutamate. Toxicol Sci. 2000;55:(1)133-42. [Rec#: 37]


76. CDC. Adverse events associated with ephedrine containing products. MMWR. 1995;45:689-93. [Rec#: 434]

77. CDC. Adverse events associated with ephedrine-containing products. JAMA. 1996;276;(21)1711-2. [Rec#: 436]


80. Chance MRA. Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. J Pharmacol Exper Therapeut. 1946;87:214-19. [Rec#: 51]


87. Chen KK, Kao CH. Ephedrine and pseudoephedrine, their isolation, constitution, isomerism, properties, derivatives and synthesis. J Am Pharmaceut Assoc. 1926;15:(8)625-639. [Rec#: 409]


90. Chen KK, Poth EI. The racial difference of the mydriatic action of ephedrines, cocaine, and euphthalmine. Proc Soc Exper Biol Med. 1927;25;(2)150-151. [Rec#: 413]
Articles Excluded from Efficacy Analysis (continued)

91. Chen KK, Schmidt CF. The action of ephedrine, the active principle of the Chinese drug Ma Hung. J Pharmacol Exper Therapeut. 1924;24:339-357. [Rec#: 414]


94. Chen KK, Wu C-K, Henriksen E. Relationship between the pharmacological action and the chemical constitution and configuration of the optical isomers of ephedrine and related compounds. J Pharmacol Exper Therapeut. 1929;36:363-400. [Rec#: 57]


100. Clemons JM, Crosby SL. Cardiopulmonary and subjective effects of a 60 mg dose of pseudoephedrine on graded treadmill exercise. J Sports Med Phys Fitness. 1993;33:(4)405-12. [Rec#: 61]


22. Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. BMJ. 1996;313:(7059)756. [Rec#: 79]


131. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: "over-the-counter" drugs that interact to stimulate thermogenesis in the obese. Nutrition. 1989;5;(1)7-9. [Rec#: 82]


Articles Excluded from Efficacy Analysis (continued)


149. Escobar JI, Karno M. Chronic hallucinosis from nasal drops. JAMA. 1982;247:(13)1859-60. [Rec#: 488]


151. FDA. Center for Food Safety and Applied Nutrition. Assessment of Public Health Risks Associated with the Use of Ephedrine Alkaloid-Containing Dietary Supplements. 2000. [Rec#: 94]

152. FDA. Dietary supplements containing ephedra alkaloids. FDA docket no. 00N-1200. In: Rockville, MD: Food and Drug Administration. 2000. [Rec#: 440]

153. FDA. Spontaneous adverse events reports. available at URL: www.fda.gov/ohrms/dockets/ac/slides/3558sle/tsld003.htm.

154. Feller DR, Malspeis L. Biotransformation of D(-)-ephedrine and L(+) -ephedrine in the rabbit, in vivo and in vitro. Drug Metab Dispos. 1977;5:(1)37-46. [Rec#: 90]


156. Finer N. Present and future pharmacological approaches [obesity]. British Medical Bulletin. 1997;53:(2)409-432. [Rec#: 304]


162. Fugh-Berman A. Clinical trials of Herbs. Primary Care - Clinics Office Pract. 1997;24:(4)889-903. [Rec#: 95]


211. Hull KM, Zanzillari R, Maher TJ. Comparison between phenylpropanolamine and structurally related compounds on gastric transit in the rat. Pharmacol Biochem Behav. 1993;46:(2)411-4. [Rec#: 471]


220. Jacobs I, Bell DG. Acute physical performance effects after ingestion of ephedrine or ephedrine combined with caffeine. 2002. [Rec#: 530]


Articles Excluded from Efficacy Analysis (continued)


247. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm. 1999;56:(2)125-38; quiz 139-41. [Rec#: 150]


253. Kustrak D, Ramic A. Ephedra species and the alkaloids of this plants. Farm Glas. 1994;50:(12)321-339. [Rec#: 153]


Articles Excluded from Efficacy Analysis (continued)


268. Li Q, Li BH. [Comparison of central stimulating effects between ephedrine and apomorphine]. Zhongguo Yao Li Xue Bao. 1991;12:(5)468-71. [Rec#: 365]

269. Liljestrand SH. The action of pseudoephedrine. I. On the isolated uterus and bladder. Chung-Kuo Sheng Li Hsueh Tsah Chih. 1929;3:249-. [Rec#: 343]


Articles Excluded from Efficacy Analysis (continued)


283. Machii S. Pharmacological studies on the optical isomers of ephedrine and pseudoephedrine. Nippon Yakurigaku Zasshi. 1957;53:638-. [Rec#: 344]


285. Mahdihasan S. Ephedra the oldest medicinal plant with the history of an uninterrupted use. Ancient Sci Life. 1987;7:(2)105-9. [Rec#: 176]


Articles Excluded from Efficacy Analysis (continued)


297. McKenna D. Ma huang. INPR. 2001. [Rec#: 508]


299. McNamara SH. FDA Has Adequate Power and Authority to Protect the Public From Unsafe Dietary Supplements. HERBALGRAM. 1996;38:25-7. [Rec#: 187]


301. Midha KK, Cooper JK, McGilveray IJ. Simple and specific electron-capture GLC assay for plasma and urine ephedrine concentrations following single doses. J Pharm Sci. 1979;68(5):557-60. [Rec#: 189]


325. Nightingale SL. From the Food and Drug Administration. JAMA. 1996;275:(20)1534. [Rec#: 495]

326. Nightingale SL. From the Food and Drug Administration. JAMA. 1996;276:(21)1710. [Rec#: 502]

327. NIOSH. Registry of Toxic Effects of Chemical Substances, Centers for Disease Control and Prevention. Ephedrine. 1997. [Rec#: 208]


331. NTP. Toxicology and Carcinogenesis Studies of Ephedrine Sulfate (CAS No. 134-72-5) in F344/N Rats and B6C3F1 Mice (Feed Studies) National Toxicology Program (NTP), Research Triangle Park, NC, (NTP Technical Reports Series) No. 307. 1986. [Rec#: 211]


344. Pentel P. Toxicity of over-the-counter stimulants. JAMA. 1984;252:(14)1898-903. [Rec#: 368]


Articles Excluded from Efficacy Analysis (continued)


361. Renwick AG. The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values. Regul Toxicol Pharmacol. 1995;22:(3)250-61. [Rec#: 234]


365. Rosene JM, Rosene JA, Kocjanzowski DL, Paolone VJ. Decongestant effects on hemodynamics at rest, exercise, and recovery from exercise during−6 degrees of head down tilt. Aviat Space Environ Med. 1999;70:(1)115-21. [Rec#: 237]


Articles Excluded from Efficacy Analysis (continued)


374. Schryver T. The buzz about ephedra and caffeine. Dietitian's Edge. 2001;March Apr:30-31, 33-34. [Rec#: 315]


Articles Excluded from Efficacy Analysis (continued)


400. Tinsley JA. The hazards of psychotropic herbs. Minn Med. 1999;82:(5)29-31. [Rec#: 259]


408. Unger DL. Blood pressure and pulse rate changes in hypertensive asthmatic patients: effects of an ephedrine compound. Ann Allergy. 1968;26:(12)637-8. [Rec#: 429]


411. USDA. Dietary supplements containing ephedrine alkaloids; proposed rule. 21 CFR 111. Federal Register. 1997;62:(107)30677-724. [Rec#: 445]


Articles Excluded from Efficacy Analysis (continued)

424. Webb AA, Shipton EA. Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for Caesarean section. Can J Anaesth. 1998;45:(4)367-9. [Rec#: 458]


444. Yale Hemorrhagic Stroke Project Final Study Report. The safety of phenylpropanolamine hydrochloride (PPA) used in OTC weight control and nasal decongestant drug products. 2000. [Rec#: 293]


## Case Report and Case Series Articles Identified

<table>
<thead>
<tr>
<th>ID#</th>
<th>Authors</th>
<th>Title</th>
<th>Journal</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>79</td>
<td>Doyle, H, Kargin, M.</td>
<td>Herbal stimulant containing ephedrine has also caused psychosis.</td>
<td>BMJ.</td>
<td>1996;313(7059):756.</td>
</tr>
<tr>
<td>174</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID#</th>
<th>Authors</th>
<th>Title</th>
<th>Journal</th>
<th>Page(s)</th>
</tr>
</thead>
</table>
Case Report and Case Series Articles Identified (continued)


